Sanofi Delivers Q1 2015 Business EPS Growth Of 2.6% At CER And 12.8% On A Reported Basis

April 30, 2015 |

6 min read

PARIS, April 30, 2015 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN)

	Q1 2015	Change (reported)	Change (CER)
Net sales	8,810 m	+12.3%	+2.4%
Business net income⁽¹⁾	1,726 m	+11.6%	+1.6%
Business EPS⁽²⁾	1.32	+12.8%	+2.6%

In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income⁽¹⁾ is a non-GAAP financial measure. ⁽²⁾(EPS) Earnings Per Share

Sanofi Chief Executive Officer, Olivier Brandicourt commented:
“Sanofi had a good start to 2015. Our businesses provide a solid foundation for our new-product cycle. Sanofi’s recent launches along with the ongoing regulatory reviews and planned submissions before year-end will drive future growth. At this important time for the company, my primary focus will be on maximizing the value of this innovative product portfolio and further establishing Sanofi as a leading biopharmaceutical company.”

Experience the interactive Multimedia News Release here: http://www.multivu.com/players/English/7507551-sanofi-results-q1-2015/

Olivier Brandicourt, Chief Executive Officer

Sanofi growth driven by Genzyme and Merial

Group sales increased 2.4% (+12.3% on a reported basis) to 8,810 million
Slightly lower Diabetes sales (-3.2%) reflects expected pricing impact on Lantus^® in the U.S.
Genzyme delivered 30.9% growth mainly driven by Aubagio^®
Animal Health recorded a strong quarter (+13.5%) driven by performance of NexGard^®
Vaccines (-4.6%) declined due to expected delay in Southern Hemisphere influenza campaign
Emerging Markets sales up 7.3%

Solid financial performance

Business net income⁽¹⁾ grew 1.6% at CER (up 11.6% on a reported basis) to 1,726 million despite launch investments and U.S. Lantus^® pricing impact
Business EPS⁽²⁾ was up 2.6% at CER to 1.32 and increased 12.8% on a reported basis

Significant achievements with new product launches

Toujeo^® was launched in the U.S. and approved in EU
Cerdelga^® approved in Europe and in Japan
Lemtrada^® sales benefited from market introduction in the U.S.
Dengue vaccine rolling submission initiated in 6 endemic countries in Asia and Latin America
Results of ELIXA cardiovascular safety with lixisenatide support U.S. resubmission in Q3 2015

Further progress in R&D

Phase III study of dupilumab in moderate-to-severe asthma initiated
Phase IIb of the IL4/IL13 bi-specific mAb in idiopathic pulmonary fibrosis started

R&D Update

Regulatory updates since the publication of the 2014 results on February 5, 2015 include the following:

In April, the FDA granted Fast Track designation to GZ/SAR402671, Genzyme’s oral substrate reduction therapy, for the treatment of Fabry disease.
In March, Quadracel^® (Diphtheria, tetanus, pertussis, polio vaccine) was approved in the U.S. in children 4-6 years of age.
In March, Cerdelga^® (eliglustat), an oral treatment for certain adults living with Gaucher disease type 1, was approved in Japan and in February in Australia.
In February, the U.S. Food and Drug Administration (FDA) approved Toujeo^®, a next generation basal insulin used to treat adults with type 1 and type 2 diabetes. In April, Toujeo^® was also approved in EU.

At the end of April 2015, the R&D pipeline contained 37 projects (excluding Life Cycle Management) and vaccine candidates in clinical development of which 12 are in Phase III or have been submitted to the regulatory authorities for approval.

2015 Guidance

Sanofi continues to expect 2015 Business EPS⁽¹⁾ to be stable to slightly growing versus 2014 at constant average exchange rates, barring major unforeseen adverse events.
In addition, the positive currency impact on 2015 full-year business EPS is estimated to be approximately +12%, under the assumption that exchange rates remain stable in the following three quarters at the average rates of March 2015.

To access the full press release of the Q1 2015 results, please click here.

Forward-Looking Statements
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2014. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US. For more information on Sanofi US, please visit http://www.sanofi.us or call 1-800-981-2491.

Sanofi US is also on Twitter and Facebook. Visit us at https://twitter.com/SanofiUS and http://www.facebook.com/sanofiUS.

Media Relations:
908-989-0726
Email: USMediaRelations@Sanofi.com

Investor Relations:
908-981-5560
E-mail: IR@sanofi.com